AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TOKYO & MUNICH--(BUSINESS WIRE)--The European Medicines Agency (EMA) has validated two marketing authorization applications (MAAs) for Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) datopotamab deruxtecan (Dato-DXd) in two types of cancer. One MAA is for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who require systemic therapy following prior treatment. The other MAA is for the treatment of adult patients.

Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer

U.S. District Judge Colm Connolly's decision comes one day before manufacturers have to respond to Medicare's initial price offers for their drugs.

Judge rejects AstraZeneca's challenge to Medicare drug price negotiations

Apple

Amazon

ASML Hld

Alphabet

GlaxoSmithKline

L'Oreal SA

LVMH Moet Hennessy Louis Vuitton

Microsoft

Netflix

Nestle SA

NVIDIA

Novo Nordisk

Novartis

Roche Holding AG

SAP SE

Sanofi

Tesla

Wall Street loves a good story, as evidenced by the recent focus on a group of stocks called the “GRANOLAS.” These are a group of 11 European stocks that have led Europe's stock markets higher.

‘GRANOLAS' vs. the Magnificent Seven: Which should you dig into now?

Lockheed Martin

Newmont Mining

Even after aggressive contractionary monetary policies by the federal reserve, inflation has remained relatively stubborn. Supply-chain issues and an increase in price of agricultural commodities are some factors that have contributed to high inflation.

3 Inflation-Resilient Stocks to Weather the Economic Turbulence

NASHVILLE, Tenn.--(BUSINESS WIRE)--Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, announced today a collaboration with AstraZeneca, a global, science-led biopharmaceutical company, aimed at advancing innovative technology and operational synergies to enhance the delivery of oncology clinical trials. Working together, SCRI and AstraZeneca will implement modern solutions to accelerate clinical trial de.

SCRI Announces a Collaboration with AstraZeneca Focused on Technology Enhancements & Innovative Operational Model to Advance Cancer Research

FibroGen

FibroGen Inc said on Monday it is regaining rights to the anemia drug, roxadustat, from AstraZeneca after the companies mutually agreed to terminate their collaboration agreement.

FibroGen regains rights to anemia drug from AstraZeneca

There is a different breed of stocks that investors should be aware of. They are GRANOLAS stocks which can be loosely thought of as the Magnificent Seven, but for European stocks.

Move Over Magnificent 7, Say Hello to the GRANOLAS

Sodexo and AstraZeneca extend their global partnership for a further 5 years. Issy les Moulineaux, February 22, 2024 Sodexo reinforces its contract of Food and Facilities Management Services with AstraZeneca in the UK, Sweden, Denmark, Finland, and Norway for a further 5-year period.

Sodexo and AstraZeneca extend their global partnership for a further 5 years.

AstraZeneca's (LON: AZN) stock surged on the FTSE 100 index following the announcement of the approval of its lung-cancer drug Tagrisso, in combination with chemotherapy. AstraZaneca's shares were up by 3%, or 304.0 pence, reaching 10,398 pence.

AstraZeneca's stock surges on FTSE 100 on Tagrisso approval

AstraZeneca PLC (LSE:AZN) is set to see a sales boost from new lung cancer treatments, according to UBS analysts, after the pharmaceuticals firm updated on two treatments on Monday. UBS anticipated peak sales of US$2.5 billion for Dato-DXd, which saw its application accepted by the US Food and Drug Administration on Monday.

AstraZeneca's new lung cancer drugs to boost sales - UBS

AstraZeneca PLC (LSE:AZN) shares swung 4% higher on Monday after it emerged that blockbuster drug Tagrisso (osimertinib), with the addition of chemotherapy, has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). The approval followed a priority review by the Food and Drug Administration (FDA) based on the results from the FLAURA2 Phase III trial published in The New England Journal of Medicine.

AstraZeneca rallies as results show Tagrisso slows lung cancer progression

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the U.S. for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have received prior systemic therapy. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly develo.

Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer

A combination of AstraZeneca's blockbuster cancer drug Tagrisso with chemotherapy to treat a type of lung cancer has been approved by the U.S. Food and Drug Administration (FDA), the company said in a statement on Friday.

U.S. FDA approves AstraZeneca's Tagrisso-chemo combo

Amgen

Biogen

Bristol-Myers

Gilead Sciences

Last October, life sciences giant Thermo Fisher Scientific (NYSE: TMO ) inadvertently laid out the case for contrarian biotech stocks. According to Reuters, the company revealed that a slump in demand from the biotech sector for its services could extend into 2024.

7 Contrarian Biotech Stocks to Consider Amid Sector Weakness

DexCom

Eli Lilly

Pfizer

Viking Therapeutics

It is entirely fair to state that weight loss treatments have massive transformational power. US FDA approval of weight loss medicines could help shrink millions of waistlines.

7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution

Altria

Starbucks

Finding good, bargain-priced stocks is difficult in a market regularly hitting new all-time highs. Although you can buy many cheap stocks, they are cheap for a reason.

3 Stocks at 52-Week Lows to Buy Before They Rebound

AstraZeneca PLC (LSE:AZN) was among the FTSE 100's big fallers on Monday as debate raged on around the company's year-end earnings late last week. AstraZeneca found itself still reeling from what the market deemed disappointing earnings, with brokers having punished the pharmaceuticals giant over an unchanged dividend and lack of research and development newsflow.

AstraZeneca slides as argument continues to surround results

Some of the biggest European stocks offer a better risk-adjusted return than the Magnificent 7, and that's not their only quality.

Nervous About Nvidia, Tesla and the Magnificent 7? Look at Goldman's GRANOLAS.

For all the attention paid to the highflying tech giants dubbed the Magnificent Seven, there's another grouping that has kept right up with them, and with a lot lower risk.

This grouping of stocks has actually kept up with the Magnificent Seven, and with a lot less risk

Alibaba

Alibaba Group is deeply discounted and offers investors great exposure to the Chinese market. United Parcel Service is coming off a tough year, but the industry leader is not likely to stay down for long.

Got $5,000? These 3 Stocks Are Near Their 52-Week Lows and Are Underrated Buys

AstraZeneca PLC (LSE:AZN) faced a blow on Friday after Deutsche Bank analysts downgraded the pharmaceuticals giant on what they labelled a “thoroughly disappointing” end to 2023. Analysts wrote in a note that they saw shares in AstraZeneca falling over 300p on Thursday's closing price to 9,500p, compared to previous guidance of a rise to 11,000p.

AstraZeneca downgraded as analysts highlight ‘underwhelming' year end

Ambev

Adyen NV

Allegion

Assa Abloy AB

Baidu

British American Tobacco

Anheuser-Busch InBev

Cie Financiere Richemont SA

FANUC Corp

Imperial Brands PLC

JD.com

Kao Corp

Medtronic

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

International Wide-Moat Stocks On Sale - The February 2024 Heat Map

LUND, SWEDEN / ACCESSWIRE / February 9, 2024 / BioInvent International (STO:BINV) Clinical supply agreement with AstraZeneca to support Phase 1/2a BI-1206 combination study BI-1206 to be evaluated in combination with Calquence® and rituximab in Phase 1/2a trial in non-Hodgkin's lymphoma The ongoing rituximab combination trial will be expanded to include the triplet arm Lund, Sweden - February 9, 2024 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced a clinical supply agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to evaluate BioInvent's anti-FcyRIIB antibody, BI-1206, in combination with rituximab and Calquence® (acalabrutinib), in a Phase 1/2a study in non-Hodgkin's lymphoma (NHL). Under the terms of the supply agreement, AstraZeneca will provide Calquence, a selective inhibitor of Bruton's tyrosine kinase (BTK), for use in combination with BI-1206 and rituximab in the ongoing Phase 1/2a clinical study (NCT03571568) for the treatment of patients with follicular lymphoma who have progressed or are refractory to rituximab.

BioInvent to Evaluate BI-1206 in Combination with Rituximab and Calquence

Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Astrazeneca (AZN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

AstraZeneca PLC (AZN) Q4 2023 Earnings Call Transcript

News for AstraZeneca Stock (AZN)